Formulation Featured Articles

  1. Addressing The Particulate Challenge In Cell Therapy Products 7/15/2026

    Cell therapy products challenge traditional particulate controls. One expert explains detection, mitigation, and contamination prevention.

  2. Platform Strategy For Improving Manufacturability And Efficacy In Bispecific Antibodies 7/15/2026

    Novel bispecific antibody engineering overcomes assembly and manufacturability challenges, enabling scalable production while preserving therapeutic function, stability, purity, and product quality.

  3. What's Hot In Freeze Drying? Your Lyophilization Questions Answered 7/8/2026

    Improve lyophilization outcomes by optimizing formulation, cycle parameters, and scale-up strategies to reduce variability and enhance stability across development.

  4. Self-Amplifying RNA: The Next Chapter In mRNA Therapeutics 6/5/2026

    Self-amplifying RNA builds on mRNA technology by enabling intracellular replication, delivering stronger and longer-lasting responses at lower doses while improving scalability, cost-efficiency, and global accessibility.

  5. A Viral Testing Facility – Striving For Excellence 5/27/2026

    A GLP-certified viral testing facility ensures biologics safety through comprehensive detection and clearance services, supporting compliance and consistent production of high-quality therapeutics.

  6. Managing Volatility, Complexity, And Risk In Injectable Manufacturing 5/26/2026

    Modern injectables raise sterile fill–finish complexity and risk, making capacity, yield protection, integrated analytics, and supply‑chain resilience essential from development to commercial launch.

  7. Keeping mAb Aggregation Low During The Final UF/DF Step 5/22/2026

    mAb aggregation can arise from molecular properties, process conditions, and equipment‑driven stress. Learn where aggregation risk increases across downstream processing and formulation.

  8. Enhancing Biologics Developability With Predictive In Silico Modelling 5/19/2026

    Predictive in silico modeling accelerates biologics development by identifying stability and formulation risks early, enabling smarter candidate selection, reduced costs, and improved success rates.

  9. In Vivo Manufacturing: When The Body Becomes The Bioreactor 5/15/2026

    Breakthrough therapies are reshaping medicine, but manufacturing complexity is holding them back. Discover how rethinking production and delivery could expand reach and improve patient experience.

  10. Can A Biotech Create A CDMO Market? 5/11/2026

    Can a biotech create a CDMO market? GeoVax, an infectious disease/oncology biotech, may have just done so. David Dodd, CEO, believes we should all concentrate more on whether the outsourcing model can align with evolving technology platforms. Both sponsors and CDMOs may need to change things up.